4-氟-2-碘-6-甲基苯甲酸甲酯 | 877151-07-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-氟-2-碘-6-甲基苯甲酸甲酯
• 英文名称: 4-fluoro-2-iodo-6-methylbenzoic acid methyl ester
• 英文别名: Methyl 4-fluoro-2-iodo-6-methylbenzoate
• CAS: 877151-07-0
• 化学式: C₉H₈FIO₂
• 分子量: 294.064
• InChiKey: OEAASKJQPCOIPV-UHFFFAOYSA-N

物化性质

• 沸点：
  269.4±35.0 °C(Predicted)
• 密度：
  1.730±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-氟-2-碘-6-甲基苯甲酸甲酯 在 N-溴代丁二酰亚胺(NBS) 、 过氧化苯甲酰 作用下， 反应 4.0h， 生成 methyl 2-(bromomethyl)-4-fluoro-6-iodobenzoate
  参考文献：
  名称：

  立体特异性PARP-1抑制剂异吲哚啉酮NMS-P515的发现

  摘要：

  聚（ADP-核糖）聚合酶-1（PARP-1）是一种参与DNA单链断裂的信号传导和修复的酶。PARP-1使用NAD +通过连接聚（ADP-核糖）链来修饰底物蛋白。正如用于治疗卵巢，乳腺和前列腺肿瘤的市售药物（例如Lynparza，Rubraca，Zejula和Talzenna）的数量所证明的那样，PARP-1是肿瘤学中公认的靶标。研究先前鉴定的异吲哚啉酮羧酰胺系列的未知区域（S）-13（NMS-P515）的努力，这是一种在生物化学（K d：0.016μM）和细胞内（IC 50）的有效PARP-1抑制剂：0.027μM）分析。共晶结构可以解释NMS-P515对靶标的立体特异性抑制。在排除了体内和体外对映体纯度的潜在损失后，以不对称方式合成了NMS-P515。NMS-P515 ADME概况及其在小鼠异种移植癌模型中的抗肿瘤活性使该化合物符合进一步优化的条件。

  DOI：

  10.1021/acsmedchemlett.8b00569
• 作为产物：
  描述：

  4-氟-2-甲基苯甲酸 在 碘苯二乙酸 、 碘 、 palladium diacetate 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 20.25h， 生成 4-氟-2-碘-6-甲基苯甲酸甲酯
  参考文献：
  名称：

  Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy

  摘要：

  The nuclear protein poly(ADP-ribose) polymerase-1 (PARP-1) has a well-established role in the signaling and repair of DNA and is a prominent target in oncology, as testified by the number of candidates in clinical testing that unselectively target both PARP-1 and its closest isoform PARP-2. The goal of our program was to find a PARP-1 selective inhibitor that would potentially mitigate toxicities arising from cross-inhibition of PARP-2. Thus, an HTS campaign on the proprietary Nerviano Medical Sciences (NMS) chemical collection, followed by SAR optimization, allowed us to discover 2-[1-4,4-difluorocyclohexyl)piperidin-4-yl] -6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118, 20by). NMS-P118 proved to be a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles and high efficacy in vivo both as a single agent and in combination with Temozolomide in MDA-MB-436 and Capan-1 xenograft models, respectively. Cocrystal structures of 20by with both PARP-1 and PARP-2 catalytic domain proteins allowed rationalization of the observed selectivity.

  DOI：

  10.1021/acs.jmedchem.5b00680

文献信息

• [EN] ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS<br/>[FR] COMPOSES A BASE D'ISOINDOLONE ET LEUR UTILISATION COMME POTENTIALISATEURS DU RECEPTEUR METABOTROPIQUE DU GLUTAMATE
  申请人：ASTRAZENECA AB

  公开号：WO2006020879A1

  公开（公告）日：2006-02-23

  The present invention is directed to compounds of formula (I), wherein R1 is a ring and n is a number from 1 to 8. The invention also relates to use of the compounds in therapy as metabotropic glutamate receptor modulators, particularly in neurological and psychiatric disorders.

  本发明涉及式(I)的化合物，其中R1是一个环，n是1到8之间的数字。该发明还涉及将这些化合物用于治疗作为代谢型谷氨酸受体调节剂，特别是在神经系统和精神疾病中的用途。
• [EN] 4-CARBOXAMIDO-ISOINDOLINONE DERIVATIVES AS SELECTIVE PARP-1 INHIBITORS<br/>[FR] DÉRIVÉS DE 4-CARBOXAMIDO-ISOINDOLINONE EN TANT QU'INHIBITEURS SÉLECTIFS DE PARP-1
  申请人：NERVIANO MEDICAL SCIENCES SRL

  公开号：WO2014064149A1

  公开（公告）日：2014-05-01

  There are provided substituted 4-carboxamido-isoindolinone derivatives which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

  提供了替代的4-羧胺基异吲哚啉酮衍生物，可以选择性地抑制与PARP-2相比的聚(ADP-核糖)聚合酶PARP-1的活性。因此，本发明的化合物在治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病方面是有用的。本发明还提供了制备这些化合物的方法、包含这些化合物的药物组合物以及利用包含这些化合物的药物组合物治疗疾病的方法。
• Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
  申请人：Clayton Joshua

  公开号：US20090275578A1

  公开（公告）日：2009-11-05

  The present invention is directed to compounds of formula I: wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 and n are as defined for formula I in the description. The invention also relates to processes for the preparation of the compounds and to new intermediates employed in the preparation, pharmaceutical compositions containing the compounds, and to the use of the compounds in therapy.

  本发明涉及式I的化合物：其中R1，R2，R3，R4，R5，R6，R7，R8，R9和n在描述中定义为式I。本发明还涉及制备该化合物的过程，以及用于制备的新中间体，含有该化合物的制药组合物，以及在治疗中使用该化合物。
• 3-OXO-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES AS PARP INHIBITORS
  申请人：Papeo Gianluca Mariano Enrico

  公开号：US20120245142A1

  公开（公告）日：2012-09-27

  There are provided substituted 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide derivatives (I) which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating, diseases utilizing pharmaceutical compositions comprising these compounds.

  本发明提供了替代的3-氧代-2,3-二氢-1H-异吲哚-4-羧酰胺衍生物（I），其能够选择性地抑制PARP-1相对于PARP-2的活性。因此，本发明的化合物可用于治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病。本发明还提供了制备这些化合物的方法、包含这些化合物的制药组合物以及利用包含这些化合物的制药组合物治疗疾病的方法。
• 3-0X0-2,3-DIHYDRO-1H-ISOINDOLE-4-CARBOXAMIDES WITH SELECTIVE PARP-1 INHIBITION
  申请人：Papeo Gianluca Mariano Enrico

  公开号：US20120245143A1

  公开（公告）日：2012-09-27

  There are provided substituted 3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide derivatives (I) which selectively inhibit the activity of poly (ADP-ribose) polymerase PARP-1 with respect to poly (ADP-ribose) polymerase PARP-2. The compounds of this invention are therefore useful in treating diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation. The present invention also provides methods for preparing these compounds, pharmaceutical compositions comprising these compounds, and methods of treating diseases utilizing pharmaceutical compositions comprising these compounds.

  提供了替代3-氧代-2,3-二氢-1H-异吲哚-4-羧酰胺衍生物(I)，其对聚(ADP-核糖)聚合酶PARP-1的活性具有选择性抑制作用，相对于聚(ADP-核糖)聚合酶PARP-2。因此，本发明的化合物可用于治疗癌症、心血管疾病、中枢神经系统损伤和不同形式的炎症等疾病。本发明还提供了制备这些化合物的方法，包括这些化合物的制药组合物，以及利用这些化合物的制药组合物治疗疾病的方法。